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Background: 18F-fluoro-deoxy-glucose (18 F-FDG) positron emission tomography integrated/combined with
computed tomography (PET-CT) provides the best diagnostic results in the metabolic characterization of
undetermined solid pulmonary nodules. The diagnostic performance of 18 F-FDG is similar for nodules measuring at
least 1 cm and for larger masses, but few data exist for nodules smaller than 1 cm.
Case presentation: We report five cases of oncologic patients showing focal lung 18 F-FDG uptake on PET-CT in
nodules smaller than 1 cm. We also discuss the most common causes of 18 F-FDG false-positive and false-negative
results in the pulmonary parenchyma.
In patient 1, contrast-enhanced CT performed 10 days before PET-CT did not show any abnormality in the site of
uptake; in patient 2, high-resolution CT performed 1 month after PET showed a bronchiole filled with dense material
interpreted as a mucoid impaction; in patient 3, contrast-enhanced CT performed 15 days before PET-CT did not
identify any nodules; in patients 4 and 5, contrast-enhanced CT revealed a nodule smaller than 1 cm which could not
be characterized. The 18 F-FDG uptake at follow-up confirmed the malignant nature of pulmonary nodules smaller
than 1 cm which were undetectable, misinterpreted, not recognized or undetermined at contrast-enhanced CT.
Conclusion: In all five oncologic patients, 18 F-FDG was able to metabolically characterize as malignant those nodules
smaller than 1 cm, underlining that: 18 F-FDG uptake is not only a function of tumor size but it is strongly related to
the tumor biology; functional alterations may precede morphologic abnormalities. In the oncologic population,
especially in higher-risk patients, PET can be performed even when the nodules are smaller than 1 cm, because it
might give an earlier characterization and, sometimes, could guide in the identification of alterations missed on CT.
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The metabolic characterization of undetermined solid pul-
monary nodules detected at computed tomography (CT) is
one of the first indications for 18 F-fluoro-deoxy-glucose
(18F-FDG) positron emission tomography (PET) [1]. In this
setting, integrated 18 F-FDG PET-CT provides higher values
of sensitivity, specificity, and accuracy (97%, 85%, 93%,
respectively) when compared with 18 F-FDG PET alone [2].
The diagnostic performance of 18 F-FDG is similar for
nodules measuring at least 1 cm and for larger masses, but* Correspondence: ml.calcagni@rm.unicatt.it
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reproduction in any medium, provided the orfew data exist on its diagnostic performance for nodules
smaller than 1 cm [3]. The few false-negative 18 F-FDG
results can be related to ‘metabolic’ causes such as low
18 F-FDG avidity, or to ‘technical’ aspects, commonly
related to the nodule size [2]. Likewise, false-positive
18 F-FDG results can be related to ‘metabolic’ causes such
as inflammatory processes, or to ‘technical’ aspects such as
micro-embolisms provoked during the tracer injection.
Herein we report on five cases of focal lung 18 F-FDG
uptake in pulmonary nodules smaller than 1 cm, and we
briefly discuss the most common causes of 18 F-FDG
false-positive and false-negative results in the pulmonary
parenchyma.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Case 1: ‘the undetectable nodule’
A 72-year-old male patient, current smoker, with no onco-
logical history, underwent whole-body contrast-enhanced
CT in June 2010 because of persistent cough and dyspnoea.
CT revealed a mass in the upper right lobe of the lung and
the biopsy proved a squamous cell carcinoma. PET-
CT performed 1 week later for staging showed intense
18 F-FDG uptake in the pulmonary mass with a central
photopenic area (SUV maximum 11.6). In addition, there
was a focus of 18 F-FDG activity localized in the subpleural
parenchyma of the apical segment of the lower right lobe,
with no significant alteration at the co-registered unen-
hanced CT images (Figure 1a and b). A technical aspect
responsible for an 18 F-FDG artifact (micro-embolism due
to the tracer injection) was excluded; the 18 F-FDG activity
was considered non-specific also due to the absence of any
suspicious morphological findings at the whole-body
contrast-enhanced CT (Figure 1c). After surgeon consult-
ation, in August 2010 the patient underwent an upper right
lobectomy with regional lymphoadenectomy: histology
confirmed a moderately differentiated (G2) squamous cell
carcinoma with large necrotic areas and no lymph nodeFigure 1 The undetectable nodule. 18 F-FDG PET-CT (June 2010): CT (a) a
subpleural parenchyma of the apical segment of the right lower lobe. (c) C
in the site of 18F -FDG uptake. (d) Contrast-enhanced CT axial image (Janua
right lower lobe, corresponding to the site of 18F -FDG uptake is revealed. 1
evidence in the apical segment of the right lower lobe of a pulmonary nodmetastases (pT2bN0). A whole-body contrast-enhanced
CT performed 4 months later for re-evaluation revealed a
pulmonary nodule of 1 cm located in the apical segment of
the lower right lobe, suspicious for malignancy (Figure 1d).
PET-CT was required for characterization: the scan showed
intense 18 F-FDG uptake (SUV maximum 10) in the nod-
ule, corroborating its malignancy. It was located in exactly
the same area as the focus of 18 F-FDG activity at the previ-
ous PET-CT (Figure 1e and f). CT-guided biopsy was
attempted but it failed because the technical limits due to
the interposition of the arch rib and the transverse process.
Taking into account all clinical and diagnostic imaging
results, the oncologists considered the nodule of neoplastic
nature and stereotactic radiotherapy was planned.
Case 2: ‘the misinterpreted nodule’
A 69-year-old male patient, a long-time smoker (20
pack-years smoking history), presented with chronic
obstructive pulmonary disease (COPD) and a history of
three different cancers: laryngeal cancer treated with
laryngectomy in 1990; pulmonary adenocarcinoma (pT1;
G2) treated with wedge resection of the upper right lobe
and adjuvant chemotherapy in 2007; and prostate cancernd fused (b) axial images. Focal 18 F-FDG uptake is evident in the
ontrast-enhanced CT axial image (June 2010): no significant alterations
ry 2011): a pulmonary nodule of 1 cm in the apical segment of the
8 F-FDG PET-CT (April 2011): CT (e) and fused (f) axial images. Clear
ule characterized by intense metabolic activity.
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and whole-body CT for follow-up in 2008 did not show
any abnormal finding; 18 F-FDG PET-CT performed in
June 2009 showed focal 18 F-FDG uptake (SUV max-
imum 1.9) in the posterior segment of the upper right
lobe of the lung, projecting onto a vascular bifurcation of
peripheral lung vessels (Figure 2a, b, and c). The focal
18 F-FDG uptake did not correspond to any visible ana-
tomical abnormality in the lung parenchyma at the co-
registered unenhanced CT, or at the contrast-enhanced
CT performed 9 months earlier. A technical aspect re-
sponsible for an 18 F-FDG artifact was excluded. There-
fore, to clarify the nature of this PET finding, taking into
account the history and the high oncological risk of theFigure 2 The misinterpreted nodule. 18 F-FDG PET-CT (June 2009): CT (a)
the posterior segment of the upper right lobe of the lung, projecting onto
high-resolution CT image (July 2009): a rounded image interpreted as a mu
the upper right lobe. (e) Axial high-resolution CT image (October 2009): a 7
(white arrow) is revealed. 18 F-FDG PET-CT (November 2009): CT (f), PET (g)
(black arrow) characterized by intense metabolic activity in the posterior sepatient, high-resolution chest CT was advised after
3 months. A first high-resolution chest CT performed in
July 2009, showed a bronchiole filled with dense material
at the site of 18 F-FDG uptake (Figure 2d). This was inter-
preted as a mucoid impaction; a second high-resolution
chest CT, performed in October 2009, revealed a growth
of dense endobronchial material with nodular morphology
(7 mm) in the posterior segment of the upper right lobe
(Figure 2e). The nodule corresponded exactly to the focal
18 F-FDG uptake revealed at PET-CT performed 4 months
earlier and it was considered highly suspicious for malig-
nancy. Before the planned surgery, 18 F-FDG PET-CT was
repeated, confirming intense metabolic activity (SUV
maximum 7.7) only in the pulmonary nodule (Figure 2f, g,, PET (b), and fused (c) axial images. Focal 18 F-FDG uptake is evident in
a vascular bifurcation of peripheral lung vessels (black arrow). (d) Axial
coid impaction (white arrow) is evident in the posterior segment of
mm pulmonary nodule corresponding to the site of 18 F -FDG uptake
and fused (h) axial images. Clear evidence of a pulmonary nodule
gment of the upper right lobe.
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and histology revealed an undifferentiated carcinoma with
morphological and immunological aspects of a high grade
neuroendocrine carcinoma with a high mitotic index and
multiple necrotic areas.
Case 3: ‘the not recognized nodule’
An 85-year-old male patient (40 pack-years smoking his-
tory, and a non-smoker for the last 25 years) with no onco-
logical history, underwent whole-body contrast-enhanced
CT in March 2010, because of persistent haemoptysis and
dyspnoea. CT revealed a soft tissue subpleural mass in the
upper right lobe of the lung and biopsy proved an adeno-
carcinoma, G3. 18 F-FDG PET-CT, performed 2 weeks
later for staging, showed intense 18 F-FDG uptake in the
known mass of the upper right lobe. In addition, there was
a focus of intense 18 F-FDG uptake in the lung parenchyma
of the upper right lobe, projecting onto the branch vessels,
while no nodule was clearly shown at the co-registered
unenhanced CT (Figure 3a). A second reading of the
contrast-enhanced CT, guided by the PET finding, recog-
nized a small (6 mm) juxtavascular nodule at the site of
the increased 18 F-FDG uptake (Figure 3b and c). Its neo-
plastic nature was confirmed by the subsequent response
to radiation therapy. Indeed, whole-body CT performed
in September at the end of treatment, revealed a
decrease in size of the upper lobe mass, the disappear-
ance of the upper right lobe nodule, and a concomitant
bilateral pulmonary and abdominal-pelvic progression
of the disease.
Case 4: ‘the undetermined nodule’
A 70-year-old female patient presented with a history of
pancreatic cancer diagnosed in August 2008 and treated
with duodeno-cephalo-pancreasectomy and adjuvant
chemotherapy. For a re-evaluation, whole-body contrast-
enhanced CT was performed in January 2010. The CT
showed an abdominal recurrence of disease and a pul-
monary nodule of 8 mm located in the medial basal seg-
ment of the lower right lobe of the lung, in the context
of an atelectatic band. Since it was not present at a previ-
ous contrast-enhanced CT performed in January 2009, it
was considered suspect for malignancy, but it could not
be characterized because of its small size and the pres-
ence of atelectasis. A new chest contrast-enhanced CT
was advised after 3 months, but instead of CT, an
18 F-FDG PET-CT was performed in March 2010 for re-
staging. PET-CT showed intense 18 F-FDG uptake in a
solid abdominal mass anterior to the abdominal aorta,
and focal 18 F-FDG uptake in the known 8 mm pulmon-
ary nodule located in the lower right lobe, in the context
of atelectasis (Figure 4a, b, and c). After two cycles of
chemotherapy, in June 2010, the patient died because of
tumor progression.Case 5: ‘the smallest nodule’
A 76-year-old male patient presented with a history of
Hurthle cell thyroid carcinoma treated with total thyroi-
dectomy in 2003 followed by 131I-radiometabolic therapy.
In 2008 he underwent a second cycle of 131I-radiometabolic
therapy for high levels of thyroglobulin (Tg) with no evi-
dence of recurrence or metastases at 131I whole-body scin-
tigraphy. Because of progressive increase of Tg values
under suppressive hormone therapy (latest value 6 ng/mL),
in April 2010 the patient underwent 18 F-FDG PET-CT in
hypothyroid conditions for re-staging. The study showed a
focal 18 F-FDG uptake in a pulmonary micronodule of
4 mm located in the upper left lobe, compatible with
micro-metastasis (Figure 5a, b, and c). In November 2010
the Tg value under suppressive hormone therapy increased
to 9 ng/mL, and high-resolution CT showed an increase in
size of the nodule and multiple bilateral pulmonary
nodules, suggesting disease progression. The clinicians
decided to perform another 131I-radiometabolic therapy.
Discussion
Contrast-enhanced CT is the best diagnostic technique to
detect pulmonary nodules providing anatomic and mor-
phologic information [2]. One of the well-established
indications for 18 F-FDG PET-CT is the metabolic
characterization of undetermined pulmonary nodules
either in oncologic patients or in patients without any
known malignancy but with a high risk of lung cancer
[4]. The complementary roles of anatomic and meta-
bolic imaging improve the diagnostic accuracy in the
diagnosis and characterization of pulmonary nodules
[2]. The risk of malignancy in pulmonary nodules, espe-
cially in those smaller than 1 cm, depends on several
factors related to the patient, such as a clinical history of
previous malignancy, age, smoking history, and on
radiological criteria such as nodule size, margins, and
density [5-7].
The diagnostic performance of 18 F-FDG is similar for
nodules measuring at least 1 cm and for larger masses
with a sensitivity of 96% and specificity of 73% [3]. Un-
fortunately, few data exist on the diagnostic performance
of 18 F-FDG for nodules smaller than 1 cm and the rela-
tionship with the risk of malignancy. In the oncologic
population, Reinhardt et al. [8] report a PET sensitivity
of 40% and 78% in pulmonary metastases ranging from
5–7 mm and 8–10 mm, respectively. In both the oncolo-
gic and non-oncologic populations, Herder et al. [9]
report a PET sensitivity of 93% and specificity of 77% in
undetermined pulmonary nodules ≤10 mm; in the non-
oncologic high risk population, Kim et al. [2] report a
sensitivity of 50% in nodules ranging from 7–10 mm and
Divisi et al. [10] report a sensitivity of 95% in solitary
lung nodules between 5 and 9.9 mm. 18 F-FDG PET sen-
sitivity for characterizing pulmonary nodules as probably
Figure 3 The not recognized nodule. (a) 18 F-FDG PET-CT fused axial image: intense 18 F-FDG uptake in the mass of the upper right lobe.
Another focus of intense 18 F-FDG uptake was evident medially in the upper right lobe. (b, c) A retrospective analysis of contrast-enhanced CT
revealed a small nodule located near vessels corresponding to the site of 18 F-FDG uptake (white arrow).
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‘technical’ aspects, which lead to false-negative results.
The metabolic causes which can reduce sensitivity are:
(1) a high blood glucose level, because of competitive reac-
tion [11]; (2) 18 F-FDG avidity related to the histological
pattern: low in some tumor types and in slow-growing
tumors (bronchiolo-alveolar carcinoma, carcinoid, metasta-
sis of clear-cell renal-cell carcinoma, etc.) [12]; (3) the
18 F-FDG uptake related to the degree of cell differentiation:
lower in well-differentiated cells than in moderately differ-
entiated ones [13]; (4) the number of viable malignant cells.
Fischer et al. [14] demonstrated ‘in vitro’ that the theoret-
ical detection limit of 18 F-FDG is in the magnitude of 105Figure 4 The undetermined nodule. 18 F-FDG PET-CT: CT (a), PET (b), and
in the lower right lobe corresponding to the nodule located in the contextto 106 malignant cells, depending on the glucose turnover
of the specific cancer. Recently, Wahl et al. [15] reported
‘in vivo’ that the limit of 18 F-FDG PET for detecting can-
cers is generally in the magnitude of 108-109 cells, which
translates into a tumor size between 0.4 and 1 cm in
diameter.
The technical aspects that can determine an underesti-
mation of the true 18 F-FDG activity, especially in
nodules smaller than 1 cm, are: the respiratory motion
because of the displacement caused by shallow breathing,
particularly in nodules located in the periphery and in
the base of the lungs; the partial volume effect because
nodules smaller than the resolution of the PET scannersfused (c) axial images. A focus of intense 18 F-FDG uptake was evident
of an atelectatic band (black arrow).
Figure 5 The smallest nodule. 18 F-FDG PET-CT: CT (a), PET (b), and fused (c) axial images. A focal 18 F-FDG uptake was evident in a very small
nodule (black arrow) located in the upper left lobe.
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or only faintly visualized [8,16,17]. Likewise, 18 F-FDG PET
specificity for characterizing pulmonary nodules as prob-
ably malignant can be compromised by ‘metabolic’ causes
and ‘technical’ aspects, which lead to false-positive results.
The metabolic causes are: benign neoplasms (sclerosis
hemangioma, leiomyoma, and so on), infection (tubercu-
losis, sarcoidosis, and so on) or inflammation (acute inflam-
mation associated with bronchiectasis or thromboembolic
disease, and so on) [12,18-20]. To our knowledge, a pul-
monary micro-embolism provoked during 18 F-FDG injec-
tion can be considered the only reason ‘technically’
responsible for a false-positive result. The vascular endo-
thelium can be damaged by several factors, such as a para-
venous or ‘in bolo’ injection, producing micro-emboli. The
cellular activation process at the site of pulmonary micro-
emboli requires energy with a consequent increased glu-
cose uptake [21,22]. From a ‘scintigraphic’ point of view,
this is evident as a focal 18 F-FDG lung uptake but, thanks
to CT integrated with the PET scanner, its artifactual
nature should be suspected in the absence of correspond-
ing abnormalities at the co-registered CT [23].
Our first case showed focal 18 F-FDG activity in the lung
parenchyma in the absence of any detectable abnormality,
even at co-registered unenhanced CT. We could exclude
an artifact caused by the micro-embolism provoked during
injection because: we routinely inject the radiotracers
through a venous cannula avoiding a para-venous injection
and repeated blood aspirations; no bolus injection was per-
formed and no vascular activity due to a para-venous in-
jection in the arm was evident in the images. The focus of
18 F-FDG activity projecting onto the subpleural paren-
chyma was considered as non-specific, also because at
contrast-enhanced CT performed only ten days before, no
other morphological abnormalities were detectable exceptthe known mass. It is very interesting to note that the 18 F-
FDG activity was already evident 7 months before the CT
appearance of a 1 cm nodule, therefore indicating its ma-
lignant nature. The absence of a detectable nodule at the
first CT examination suggests that the area of focal 18 F-
FDG uptake contained a very small number of tumor cells,
not enough for anatomical detection, and therefore, it
would be reasonably to say around the lowest 18 F-FDG
detection limit, as reported [15]. This supports the well-
known concept that the metabolic/functional alterations
may precede the morphologic ones, and PET can some-
times detect early changes not, or only minimally revealed
by morphological imaging [24].
Also in case 2 we could exclude an artifact due to a
micro-embolism by applying the same considerations
previously described. Differently from case 1, taking into
account the very high oncologic risk of this patient, the
PET finding was considered highly suspicious for malig-
nancy, even in the absence of any clear morphologic
abnormalities at co-registered unenhanced CT. No clear
evidence of a nodule at co-registered unenhanced CT
could be explained by some technical acquisition rea-
sons: slice thickness (5 mm), free breathing and ‘low
dose’ setting (tube current of about 40 mA/s). These ac-
quisition parameters could limit the detection of small
pulmonary nodules at co-registered unenhanced PET-
CT, especially in a juxtavascular location. A volumetric
high-resolution CT was suggested to overcome these
limits; with this technique, slice thickness is 1 mm or less,
in a single, breath-held inspiration, with a full radiation
dose, allowing the identification of small pulmonary
nodules. However, a delay of 3 months was suggested to
identify dimensional growth, as this is the only reliable cri-
terion in favor of malignancy; the other criteria commonly
used to define malignancy of a nodule (dimensions, site,
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this case, PET was able to detect malignant findings earlier
than morphological imaging. No clear detection of the
nodule at co-registered unenhanced CT and also at the
first high-resolution CT suggests that the number of
tumor cells showing 18 F-FDG uptake was very low, as
previously reported for case 1 [15]. In addition, very early
18 F-FDG uptake could be explained by the high mitotic
index and by the presence of highly aggressive and undif-
ferentiated cells, as proved by histopathology.
In case 3, PET showed an intense focal 18 F-FDG uptake
in the right lung, located between two vessels, where no ab-
normalities were recognized either at the staging contrast-
enhanced CT, or at CT integrated with PET. Also in this
case we could exclude the ‘technical’ origin of a micro-
embolism. So, guided by focal 18 F-FDG uptake, we care-
fully looked for any alteration in lung parenchyma at
co-registered unenhanced CT as well as at contrast-
enhanced CT. Eventually, a small juxtavascular nodule cor-
responding to the focal uptake was recognized, and its neo-
plastic nature was confirmed by the subsequent response
to radiation therapy, even if a disease progression with mul-
tiple new pulmonary nodules and neoplastic abdominal
disease were found. Possible causes of failed identification
of pulmonary nodules at CT are a central location, either
within the bronchi (as in case 2) or adjacent to vessels, as
in this case; other possible causes are a small size, faint at-
tenuation, lower lobe location or location adjacent to other
parenchymal abnormalities such as inflammatory lesions
[28]. This case underlines the importance of looking at the
pulmonary parenchyma with high accuracy, especially in
high-risk oncological patients, searching for any abnormal-
ity and eventually using PET findings as a guide because
PET could sometimes guide the identification of alterations
missed at morphologic imaging.
In case 4, CT revealed a pulmonary nodule not present
in the previous CT scan, difficult to be characterized be-
cause of its small size and the presence of the atelectatic
band. PET performed only 1 month later demonstrated
that the nodule had metabolic activity, strongly suggesting
its neoplastic nature. Unfortunately, the patient died for
cancer progression and no proof of its true nature was
available. Multidetector CT can detect nodules as small as
1 or 2 mm but without being able to characterize them.
Nevertheless, in this case, the pulmonary nodule was char-
acterized by PET even though located at the base of right
lung, in the context of the atelectatic band and only 8 mm
in size.
In case 5, PET was able to characterize a pulmonary
micronodule of 4 mm, impossible to characterize at mor-
phologic imaging. Despite the very small size, the 18 F-FDG
uptake can be explained by ‘metabolic’ reasons such as the
aggressive histotype of the primary thyroid cancer (Hurthle
cell carcinoma), and the de-differentiation of the tumorcells, rather than their number. It has been widely demon-
strated that secondary lesions of thyroid carcinomas with
low iodine avidity tend to have higher glucose metabolism
and are more likely to be positive at 18 F-FDG PET [29].
Conclusions
In conclusion, 18 F-FDG was able to metabolically charac-
terize as malignant nodules smaller than 1 cm, underlin-
ing, although in only five oncologic patients, the following
concepts: (1) 18 F-FDG uptake is not only a function of
tumor size but it is strongly related to the tumor biology,
such as mitotic index, aggressivity, differentiation grading,
de-differentation of the cells; and (2) our five cases further
confirm the general principle that ‘functional alterations
may precede morphologic abnormalities’.
In clinical practice, in the oncologic population, especially
in higher-risk patients (such as those with multiple tumors,
with a history of recurrence, and/or with an aggressive his-
totype), PET can be performed even when the nodules are
smaller than 1 cm, because it might give an earlier
characterization. Moreover, PET could sometimes guide
the identification of alterations missed at morphologic im-
aging. It is reasonable to assume that the additional radio-
logical exposure risk (effective dose of 7–10 mSv) can be
‘balanced’ by the possibility of early diagnosis and treat-
ment of an aggressive tumor [24].
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